natgillin/translations-raw huggingface dataset:
Scintimun should only be used once in a patient’s lifetime.
Zdravilo Scintimun se lahko pri preiskovancu uporabi samo enkrat.
Scintimun vial:
Viala zdravila Scintimun:
Scissors to open the blister
škarje za odpiranje pretisnega omota
Scleral mononuclear cell infiltrates were present in 1/4 males and 1/4 females treated with 0.5 mg/ml and in 2/4 males and 1/4 females treated with1.0 mg/ml.
Mononuklearni celični infiltrati v beločnici so bili prisotni pri 1/4 samcev in pri 1/4 samic, zdravljenih z odmerkom 0,5 mg/ml, in pri 2/4 samcev in 1/4 samic, zdravljenih z odmerkom 1,0 mg/ml.
Scleritis and orbital inflammation
vnetje beločnice in orbite
Scleritis and parophthalmia
vnetje beločnice in vnetje obočesnih tkiv
Sclerodermal-like changes usually preceded by peripheral lymphedema have been reported with docetaxel.
Pri zdravljenju z docetakselom so poročali o spremembah, podobnih sklerodermalnim spremembam.
Sclerodermal-like changes usually preceded by peripheral lymphoedema have been reported with docetaxel.
Pri zdravljenju z docetakselom so poročali o spremembah podobnih sklerodermalnim spremembam.
SCN patients
Bolniki s hudo kronično nevtropenijo
SCN patients
Bolniki s SCN
Scoop size
Velikost žlice
Scoops of 1 ml and 5 ml are attached.
Priloženi sta žlički za 1 ml in 5 ml.
Scoops – two scoops measuring 1 g and 3 g of Econor 10% oral powder are supplied.
Žličke – priloženi sta dve žlički za odmero 1 g in 3 g peroralnega praška Econor 10 %.
Score
Število točk
Scotoma, scleral discolouration, mydriasis, photophobia, myopia, lacrimation increased
Redki skotom, obarvanje beločnice, midriaza, fotofobija, miopija, močnejše solzenje
SCR
SKR
SCR % (95% CI
SCR % (95-% IZ)
SCR % (95% CI))
SCR % (95-% IZ)
SCR [%] (n/N)
Vrednost serokonverzije [%] (n/N)
Screen
mrežica
Screening HIV-1 RNA (copies
Presejalna HIV-1 RNA (kopij/ml):
Screening HIV-1 RNA (copies/mL):
Presejalna HIV-1 RNA (kopij/ml):
Screening is also recommended prior to re- initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.
Presejalni test je priporočljivo opraviti tudi pred ponovno uvedbo zdravljenja z abakavirjem pri bolnikih z neznanim statusom HLA-B*5701, ki so predhodno prenašali abakavir.
Screening is also recommended prior to re- initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.
Tudi pri bolnikih, ki nimajo znanega statusa HLA-B*5701 in so v preteklosti prenašali abakavir, je priporočljivo izvesti presejanje pred ponovno uvedbo zdravljenja z abakavirjem.
Screening Viral Load >100,000 copies/mL
Presejalno virusno breme > 100.000 kopij/ml
Screw it firmly clockwise into the vial.
Čvrsto jo privijte v vialo v smeri urinega kazalca.
Screw needle on until secure.
Privijte iglo dokler ni čvrsto pritrjena.
Screw the grey needle onto the syringe and remove the cap from the grey needle.
Sivo iglo privijte na brizgo in odstranite pokrovček z igle.
Screw the lid onto the mixing bottle.
Na mešalno plastenko namestite zaporko.
Screw the needle off.
Odvijte iglo.
Screw the needle shield (containing the needle) clockwise onto the syringe.
Pokrovček (v katerem je igla) v smeri urnega kazalca privijte na injekcijsko brizgo.
Screw the needle straight and tightly onto your InnoLet (picture 1A).
Iglo naravnost in trdno privijte na injekcijski peresnik InnoLet (slika 1A)
Screw the needle straight and tightly onto your InnoLet (picture 1A).
Iglo naravnost in trdno privijte na vaš injekcijski peresnik InnoLet (slika 1A).
Screw the needle straight and tightly onto your InnoLet (picture 1B).
Iglo naravnost in trdno privijte na injekcijski peresnik InnoLet (slika 1B).
Screw the needle straight and tightly onto your InnoLet (picture 1B).
Iglo naravnost in trdno privijte na vaš injekcijski peresnik InnoLet (slika 1B).
Screw the needle straight and tightly onto your InnoLet (picture A).
Iglo naravnost in trdno privijte na vaš injekcijski peresnik InnoLet (slika A).
Screw the needle straight onto the pen.
Iglo naravnost in trdno privijte na injekcijski peresnik.
Screw the plunger rod clockwise into the plunger inside the pre-filled syringe until resistance is felt.
Privijte nosilec bata v smeri urinega kazalca v bat, ki je v notranjosti napolnjene injekcijske brizge, dokler ne začutite upora.
Screw the pre-filled pen together until the clear front part and the pen body meet.
Privijte napolnjen injekcijski peresnik do konca, dokler se prozorni sprednji del ne spoji s telesom peresnika.
Screw the pre-filled syringe on the needle still fixed in the needle cap.
Napolnjeno injekcijsko brizgo privijte na iglo, ki je še vedno zaščitena s pokrovčkom.
Screw the prefilled syringe securely onto the H vial adapter until resistance is felt.
Napolnjeno injekcijsko brizgo trdno privijte na nastavek za vialo, dokler ne začutite upora.
Screw the prefilled syringe securely onto the vial adapter until resistance is felt.
Napolnjeno injekcijsko brizgo trdno privijte na nastavek za vialo, dokler ne začutite upora.
Screw the prefilled syringe securely onto the vial H adapter until resistance is felt.
Napolnjeno injekcijsko brizgo trdno privijte na nastavek za vialo, dokler ne začutite upora.
Screw the safety needle onto the prepared syringe.
Privijte varnostno iglo na pripravljeno brizgo.
Screw the syringe containing 1.0 ml of water onto the vial adapter.
Na adapter za vialo privijte brizgo, ki vsebuje 1,0 ml vode.
Screw the transfer needle tightly onto the syringe.
Iglo za prenos trdno privijte na brizgo.
SCREW-CAP CONTAINER
VSEBNIK Z NAVOJNIM ZAMAŠKOM
SD = standard deviation d = days
SD = standardna deviacija d = dni
SD – Standard Deviation.
SD – standardna deviacija
SDAI Clinical Remissionb
Boolean klinična remisija
SE = standard error, CI= confidence interval), * p < 0.05, **p< 0.0001
SD = standardna deviacija, IZ= interval zaupanja, *p< 0,05, **p< 0,0001
SE = standard error, CI= confidence interval, * p < 0.05
SD = standardna deviacija, IZ= interval zaupanja, *p < 0,05
SE = standard error, CI= confidence interval, * p < 0.05
SD = standardna deviacija, IZ= interval zaupanja, *p< 0,05
SE = standard error, CI= confidence interval, * p < 0.05, **p < 0.0001
SD = standardna deviacija, IZ= interval zaupanja, *p< 0,05, **p< 0,0001
SE = standard error, CI= confidence interval, *p < 0.05, **p < 0.0001
SD = standardna deviacija, IZ= interval zaupanja, *p< 0,05, **p< 0,0001
SE = standard error. a. p = 0.0001.
SE = standardna napaka. a. p = 0,0001.
SE = Standard Error; CI = Confidence Interval; aMean difference is Travoprost – Timolol.
SE = standardna napaka; CI = interval zaupanja; a Srednja vrednost razlike je vrednost za travoprost minus vrednost za timolol.
SE Standard Error, SD Standard deviation, LSM Least Square Mean, LS Diff.
SE (Standard Error) - standardna napaka, SD (Standard deviation) - standardni odklon, LSM (Least Square Mean) – povprečje, izračunano po metodi najmanjših kvadratov, LS Diff.
SE-114 57 Stockholm
821 08 Bratislava, SR
SE-114 57 Stockholm SWEDEN
SE-114 57 Stockholm ŠVEDSKA
SE-15185 Södertälje SWEDEN
SE-151 85 Södertälje ŠVEDSKA
SE-16904 Solna
SE-192 07 Sollentuna
SE-212 14 Malmö Sweden
SE-141 75 Kungens Kurva Švedska
se10
kisline10
sealant
uporaba
Sealant matrix
matriks z lepilom za tkiva
sealant matrix (5.1 cm x 10.2 cm)
matriks z lepilom za tkiva (5,1 cm × 10,2 cm)
Sealant powder
prašek za lepilo za tkiva
Sealed aluminium laminate cup with a polypropylene (cup) and polypropylene/polyethylene (lid) contact layer containing 1,000, 5,000 or 10,000 doses.
Zavarjena merica iz aluminijevega laminata s polipropilenskim (merica) in polipropilensko polietilenskim (pokrovček) stičnim slojem, ki vsebuje 1.000, 5.000 ali 10.000 odmerkov.
Sealed aluminium laminate cup with a polypropylene (cup) and polypropylene/polyethylene (lid) contact layer containing 1,000; 5,000 or 10,000 doses.
Zapečatena merica iz aluminijevega laminata s polipropilenskim (merica) in polipropilensko polietilenskim (pokrovček) stičnim slojem, ki vsebuje 1.000, 5.000 ali 10.000 odmerkov.
Sealed foil pouch in cardboard carton
Zapečatena vrečka iz folije v škatli
Sealed Pack
Zalepljeno.
Sealed pack.
Zalepljeno pakiranje.
Sealing band:
Zaporni trak: želatina
Seasonal Allergic Rhinitis in adults and adolescents
Sezonski alergijski rinitis pri odraslih in mladostnikih
Seasonal Allergic Rhinitis in adults and adolescents
Sezonski alergijski rinitis pri odraslih in mladostnikih:
Seasonal allergy
ezonska alergija,
Seasonal allergy
sezonska alergija
Seat the child leaning slightly backwards.
Posedite otroka tako, da bo nagnjen rahlo nazaj.
Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL).
Sebelipaza alfa je rekombinantna humana lizosomska kisla lipaza (rhLAL-recombinant human lysosomal acid lipase).
Sebelipase alfa replaces the missing enzyme, helping to break down fats and stopping them building up in the body’s cells.
Sebelipaza alfa nadomesti manjkajoči encim, kar pomaga razgraditi maščobe in zaustavi njihovo kopičenje v celicah.
Sebivo 20 mg/ml oral solution Telbivudine
Sebivo 20 mg/ml peroralna raztopina telbivudin
Sebivo belongs to a class of medicines (a nucleoside analogue) that can cause an excess of lactic acid in the blood (lactic acidosis) and enlargement of the liver (hepatomegaly) with fatty liver (steatosis).
Sebivo sodi v skupino zdravil (nukleozidni analogi), ki lahko povzroča prevelike količine mlečne kisline v krvi (laktacidozo) in povečanje jeter (hepatomegalijo) z zamaščenostjo jeter (steatoza).
Sebivo can cause persistent unexplained muscle weakness or muscle pain (myopathy).
Zdravilo Sebivo lahko povzroča trdovratno nepojasnjeno šibkost mišic ali bolečine v mišicah (miopatijo).
Sebivo contains the active substance telbivudine.
Zdravilo Sebivo vsebuje zdravilno učinkovino telbivudin.
Sebivo does not reduce the risk of infecting others with hepatitis B virus (HBV) through sexual contact or exposure to contaminated blood or other body fluids.
Zdravilo Sebivo ne zmanjšuje tveganja, da bi druge okužili z virusom hepatitisa B (HBV) s spolnimi stiki ali preko okužene krvi ali drugih telesnih tekočin.
Sebivo film-coated tablets are white to slightly yellowish, oval, film-coated tablets with “LDT” imprinted on one side.
Sebivo filmsko obložene tablete so ovalne, bele do rahlo rumenkaste filmsko obložene tablete z vtisnjeno oznako “LDT” na eni strani.
Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
Zdravilo Sebivo je indicirano za zdravljenje kroničnega hepatitisa B pri odraslih bolnikih s kompenzirano jetrno boleznijo in znaki virusne replikacije, stalno zvišanimi koncentracijami alanin- aminotransferaze (ALT) in histološko dokazanim aktivnim vnetjem in/ali fibrozo.
Sebivo is not recommended for use in children and adolescents.
Uporaba zdravila Sebivo ni priporočljiva pri otrocih in mladostnikih.
Sebivo is to be taken orally, with or without food.
Zdravilo Sebivo je treba jemati peroralno, s hrano ali brez nje.
Sebivo is used to treat adults with chronic hepatitis B.
Sebivo se uporablja za zdravljenje odraslih s kroničnim hepatitisom B.
Sebivo may also cause other side effects:
Zdravilo Sebivo lahko povzroča tudi druge neželene učinke:
Sebivo oral solution contains approximately 47 mg sodium per 600 mg dose (30 ml), which should be taken into consideration by patients on a controlled sodium diet.
Peroralna raztopina Sebivo vsebuje približno 47 mg natrija na 600–miligramski odmerek (30 ml), kar je treba upoštevati pri bolnikih, ki se držijo diete z omejenim vnosom soli.
Sebivo tablets were compared with lamivudine (another medicine used in chronic hepatitis B) in a two- year study involving 1,367 patients.
V dvoletni študiji, ki je zajela 1 367 bolnikov, so primerjali učinkovitost tablet Sebivo z učinkovitostjo lamivudina (drugega zdravila za zdravljenje kroničnega hepatitisa B).
Sebivo with food and drink
Zdravilo Sebivo skupaj s hrano in pijačo
Seborrhoeic dermatitis*
seboreični dermatitis
Seborrhoeic dermatitis†
eboroični dermatitis
Second
drugič
Second
drugo
Second and third trimester of pregnancy (see section 4.6).
Drugo in tretje trimesečje nosečnosti (glejte poglavje 4.6).
Second and third trimester of pregnancy (see sections 4.4 and 4.6)
drugo ali tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6)
Second and third trimester of pregnancy (see sections 4.4 and 4.6)
Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Second and third trimester of pregnancy (see sections 4.4 and 4.6).
Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Second and third trimesters of pregnancy (see section 4.4 and 4.6).
Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Second and third trimesters of pregnancy (see section 4.6).
Drugo in tretje trimesečje nosečnosti (glejte poglavje 4.6)
Second and third trimesters of pregnancy (see section 4.6).
drugo in tretje trimesečje nosečnosti (glejte poglavje 4.6);
Second and third trimesters of pregnancy (see section s 4.4 and 4.6).
drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6),
Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6),
Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6)
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6),
Second degree or higher AV block has been reported in post-marketing experience.
Iz izkušenj, dobljenih v obdobju trženja, so poročali o atrioventrikularnem bloku druge ali višje stopnje.
Second dose (21 days after the first dose)
Drugi odmerek (21 dni po prvem odmerku)
Second dose (in the evening)
Drugi odmerek (zvečer)
Second dose following incomplete primary immunization (1x6 mcg)
drugi odmerek po nezaključeni primarni imunizaciji (1 x 6 mikrogramov)
Second dose reduction to:
Drugo zmanjšanje odmerka na:
Second dose reductiona: to 15 mg/m2
Drugi zmanjšani odmereka: na 15 mg/m2
Second dose: 7 days later
drugi odmerek: 7 dni pozneje
Second dose: Versican Plus DHPPi mixed with Versiguard Rabies 3–4 weeks later, but not before 12 weeks of age.
Drugi odmerek: Versican Plus DHPPi zmešamo z Versiguard Rabies 3-4 tedne kasneje, toda ne pred starostjo 12 tednov.
Second dose: Versican Plus DHPPi/L4R 3–4 weeks later but not before 12 weeks of age.
Drugi odmerek: Versican Plus DHPPi/L4R 3–4 tedne kasneje, vendar ne pred starostjo 12 tednov.
Second dose: Versican Plus Pi mixed with Versiguard Rabies 3–4 weeks later, but not before 12 weeks of age.
Drugi odmerek: Versican Plus Pi zmešamo z Versiguard Rabies 3-4 tedne kasneje, toda ne pred starostjo 12 tednov.
Second episode: reduce docetaxel dose by 20%.
Drugi pojav: zmanjšajte odmerek docetaksel za 20 %.
Second episode: reduce docetaxel dose by 20%.
drugi pojav: zmanjšajte odmerek docetaksela za 20
Second episode: reduce docetaxel dose by 20%.
Po kemoterapiji morajo bolniki prejeti še kemoradioterapijo.
Second episode: then reduce docetaxel dose by 20%.
drugi pojav: zmanjšajte odmerek docetaksela za 20
Second episode: then reduce docetaxel dose by 20%.
Drugi pojav: zmanjšajte odmerek docetaksela za 20 %.
Second infusiona
druga infuzijaa
Second injection - 1 month after the first injection.
druga injekcija - 1 mesec po prvi injekciji
Second injection: 1 month after first injection Third injection: 6 months after first injection
Drugi odmerek: 1 mesec po prvem odmerku Tretji odmerek: 6 mesecev po prvem odmerku
Second injection: 2 months after first injection
Druga injekcija: 2 meseca po prvi injekciji
Second injection: 2 months after first injection (not earlier than one month after the first dose)
Druga injekcija: 2 meseca po prvi injekciji (ne prej kot 1 mesec po prvem odmerku)
Second injection: 6 months after first injection
Druga injekcija: 6 mesecev po prvi injekciji
Second injection: after 3-4 weeks
Drugi odmerek: po 3-4 tednih
Second injection: given between 5 and 13 months after first injection
Druga injekcija: med 5. in 13. mesecem po prvi injekciji
Second injection: given between 5 and 13 months after first injection If you are 15 years old or above
Drugi odmerek: prejeli ga boste od 5 do 13 mesecev po prvem odmerku Če ste stari 15 let ali več
Second monthly weighing where bodyweight loss < 3% per month since previous weighing
Drugo mesečno tehtanje, kjer je izguba telesne mase < 3 % na mesec v primerjavi s prejšnjim mesečnim tehtanjem
Second occurrence
drugi pojav
Second treatment course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the initial treatment course.
Drugi cikel zdravljenja: 12 mg/dan 3 zaporedne dni (skupni odmerek 36 mg), ki se daje 12 mesecev po začetnem ciklu zdravljenja.
Second trimester of pregnancy (n=11)a
Drugo trimesečje nosečnosti (n=11)a
Second trimester of pregnancy (n=16)
Drugo trimesečje nosečnosti (n=16)
Second vaccination: at 17 days of age.
Drugi odmerek: pri 17 dnevih starosti
Second vaccination: at 17 days of age.
Drugi odmerek: pri 17 dnevih starosti.
Second, determine the number of capsules and the amount of vehicle (water containing 0.05 % w/v sodium benzoate added as a preservative) that is needed to prepare the total volume (calculated from the table above) of pharmacy compounded 6 mg/ml suspension as shown in the table below:
Nato določite število kapsul in količino vehikla (voda, ki vsebuje 0,05 % m/v natrijevega benzoata kot konzervans), ki so potrebni za pripravo celokupnega volumna (izračunanega iz zgornje preglednice) mg/ml suspenzije, pripravljene v lekarni, kot je prikazano v spodnji preglednici:
Second, determine the number of capsules and the amount of vehicle (water containing 0.05 % w/v sodium benzoate added as a preservative) that is needed to prepare the total volume (calculated from the table above) of pharmacy compounded 6 mg/ml suspension as shown in the table below:
Nato določite število kapsul in količino vehikla (voda, ki vsebuje 0,05% m/v natrijevega benzoata kot konzervans), ki so potrebni za pripravo celokupnega volumna (izračunanega iz zgornje preglednice) 6 mg/ml suspenzije pripravljene v lekarni, kot je prikazano v spodnji preglednici.
Second- or third- degree atrio-ventricular block, complete bundle branch block, distal block, sinus node dysfunction, atrial conduction defects, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker)
Atrioventrikularni blok druge ali tretje stopnje, popolni kračni blok, distalni blok, disfunkcija sinusnega vozla, atrijske prevodne motnje, ali bolezen sinusnega vozla (razen če ima bolnik delujoč srčni spodbujevalnik).
Second- or third-degree atrioventricular blocks
Atrioventrikularni blok druge ali tretje stopnje
Second-degree atrioventricular block was detected in less than 0.2% patients on Gilenya 0.5 mg.
Atrioventrikularni blok druge stopnje so ugotovili pri manj kot 0,2 % bolnikov, ki so jemali zdravilo Gilenya 0,5 mg.
Secondary
30. dan
Secondary composite
Sekundarni
Secondary composite endpoints
Sekundarna sestavljena opazovana dogodka
Secondary efficacy analyses over 144 weeks included the proportion of patients with HIV-1 RNA concentrations < 400 or < 50 copies/ml, and change from baseline in CD4 cell count.
Sekundarne analize učinkovitosti v 144 tednih so vključile del bolnikov s koncentracijo HIV-1 RNA < 400 ali < 50 kopij/ml in spremembo števila celic CD4 od začetka študije.
Secondary efficacy assessments included investigator- assessed ORR and PFS.
Sekundarna merila učinkovitosti so vključevala raziskovalčevo oceno deleža objektivnega odziva in preživetje brez napredovanja bolezni.
Secondary efficacy endpoints
Sekundarni cilj za oceno učinkovitosti
Secondary efficacy endpoints
Sekundarni cilji za oceno učinkovitosti
Secondary efficacy endpoints
Sekundarni učinkovitostni opazovani dogodki
Secondary efficacy endpoints included overall survival (OS), objective response rate, duration of response (DoR) as assessed by INV and PFS as assessed by an independent review facility (IRF).
Sekundarni opazovani dogodki so obsegali celokupno preživetje (OS, overall survival), objektivni delež odziva (ORR, objective response rate), trajanje odziva (DoR, duration of response) po oceni raziskovalca in PFS po oceni neodvisnega revizijskega telesa (IRF, independent review facility).
Secondary efficacy endpoints were clinical response rate, breast conserving surgery rate (T2-3 tumours only), disease-free survival (DFS), and PFS.
Sekundarni končni cilji učinkovitosti so bili delež kliničnega odgovora, delež operacij z ohranitvijo dojke med operacijo (le T2–3 tumorji), preživetje brez bolezni (DFS – disease-free survival) in preživetje brez napredovanja bolezni (PFS – progression-free survival).
Secondary efficacy endpoints were objective response rate (ORR) and overall survival (OS).
Sekundarne opazovane točke učinkovitosti so bile primerjava splošne stopnje odziva (ORR, objective response rate) in splošno preživetje (OS, overall survival).
Secondary efficacy endpoints were overall survival (OS), PFS (investigator-assessed), objective response rate (ORR), duration of response, and time to symptom progression according to the FACT B Quality of Life questionnaire.
Sekundarni cilji učinkovitosti so bili celokupno preživetje (OS – overall survival), PFS (ocenjeno s strani raziskovalca), objektivni delež odgovora (ORR – objective response rate), trajanje odgovora in čas do napredovanja simptomov glede na Vprašalnik o kakovosti življenja FACT B.
Secondary efficacy outcome measures included Duration of Response (DoR), Disease Control Rate (DCR) and Progression-Free Survival (PFS).
Sekundarna merila izida učinkovitosti so vključevala trajanje odziva (DoR – duration of response), delež obvladanja bolezni (DCR – disease control rate) in preživetje brez napredovanja bolezni (PFS – progression-free survival).
Secondary efficacy outcome measures were ORR and response duration.
Sekundarni merili izida učinkovitosti sta bili celokupni delež odgovora in trajanje odgovora.
Secondary efficacy outcome measures were overall response rate (ORR) and response duration.
Sekundarni merili izida učinkovitosti sta bili celokupni delež odgovora (ORR) in trajanje odgovora.
Secondary efficacy parameters included OFF Time, UPDRS II and III (Unified Parkinson’s Disease Rating Scale – sections II and III), and CGI-C (Clinical Global Impression of Change)
Sekundarni parametri učinkovitosti so vključevali obdobje brez težav z gibanjem, UPDRS II in III (Unified Parkinson’s Disease Rating Scale; Združena ocenjevalna lestvica Parkinsonove bolezni – rubriki II in III) ter CGI-C (Clinical Global Impression of Change; Celostni klinični odziv).
Secondary end-points included, among others, changes from baseline in: 24-hour UFC, plasma ACTH, serum cortisol levels, and clinical signs and symptoms of Cushing’s disease.
Sekundarni cilji opazovanja so bile med drugim spremembe od izhodiščnih vrednosti pri: 24-urni vrednosti UFC, vrednosti ACTH v plazmi in vrednosti kortizola v serumu ter pri kliničnih znakih in simptomih Cushingove bolezni.
Secondary endpoint
Sekundarni cilj opazovanja
Secondary endpoints
Sekundarni cilji raziskave
Secondary Endpoints
Sekundarni opazovani dogodki
Secondary endpoints (weeks 20-24)
Sekundarni opazovani dogodki (20. - 24. teden)
Secondary Endpoints - Percentage of Responders at Week 24 (b)
Sekundarni cilji – delež odzivnih bolnikov v 24. tednu (b)
Secondary Endpoints Changes from Baseline to Month 18 LSMean (Standard Error) (Intent- to-Treat Population) (Study Fx-005)
Spremembe pri sekundarnih opazovanih dogodkih od izhodišča do 18. meseca – povprečje najmanjših kvadratov (standardna napaka) (populacija ITT) (študija Fx-005)